A “new normal” for NCI-sponsored clinical trials is long overdue

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I read with interest the recently published story on the recommendations to streamline data collection in certain NCI trials presented at the Nov. 9, 2022, meeting of the Clinical and Translational Research Committee (The Cancer Letter, Nov. 11, 2022).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor emeritus, University of Chicago; Former chief medical officer and executive vice president, American Society of Clinical Oncology; Former chair, Cancer and Leukemia Group B
Table of Contents

YOU MAY BE INTERESTED IN

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion. 
Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor emeritus, University of Chicago; Former chief medical officer and executive vice president, American Society of Clinical Oncology; Former chair, Cancer and Leukemia Group B

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login